Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2018201071) B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.: WO/2018/201071 International Application No.: PCT/US2018/029993
Publication Date: 01.11.2018 International Filing Date: 27.04.2018
IPC:
A61K 35/17 (2015.01) ,A61K 48/00 (2006.01) ,C12N 5/0781 (2010.01) ,C12N 5/10 (2006.01) ,C12N 15/09 (2006.01)
[IPC code unknown for A61K 35/17]
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48
Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
07
Animal cells or tissues
071
Vertebrate cells or tissues, e.g. human cells or tissues
078
Cells from blood or from the immune system
0781
B cells; Progenitors thereof
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
5
Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
10
Cells modified by introduction of foreign genetic material, e.g. virus-transformed cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
Applicants:
IMMUSOFT CORPORATION [US/US]; 454 N 34th St. Seattle, WA 98103, US
Inventors:
SCHOLZ, Matthew, Rein; US
HERBIG, Eric, J.; US
MCIVOR, R., Scott; US
DE LAAT, Rian; US
OLSON, Erik; US
Agent:
NUDELMAN, Aaron, S.; US
CHRISTIANSEN, William, T.; US
LAHERTY, Carol, D.; US
ROGEL, Mark, E.; US
TEAGUE, Lawrence, J.; US
Priority Data:
62/491,15127.04.2017US
Title (EN) B CELLS FOR IN VIVO DELIVERY OF THERAPEUTIC AGENTS AND DOSAGES THEREOF
(FR) LYMPHOCYTES B POUR L’ADMINISTRATION IN VIVO D’AGENTS THÉRAPEUTIQUES ET DOSES DE CEUX-CI
Abstract:
(EN) The present invention relates to methods for administering autologous and/or allogeneic B cells genetically modified to produce a therapeutic agent, such as a therapeutic protein. Specifically disclosed are methods for administering a single, maximally effective dose of genetically modified B cells and for administering multiple doses of genetically modified B cells. The compositions and methods disclosed herein are useful for the long-term, in vivo delivery of a therapeutic agent.
(FR) La présente invention concerne des procédés d’administration de lymphocytes B autologues et/ou allogéniques génétiquement modifiées pour produire un agent thérapeutique, tel qu’une protéine thérapeutique. L’invention concerne spécifiquement des procédés d’administration d’une dose unique, d’efficacité maximale, de lymphocytes B génétiquement modifiés et d’administration de doses multiples de lymphocytes B génétiquement modifiés. Les compositions et les procédés de l’invention sont utiles pour l’administration in vivo, à long terme, d’un agent thérapeutique.
front page image
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: English (EN)
Filing Language: English (EN)